Department of Spine Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
Department of Spine Surgery, People's Hospital of Ganxian District, Ganzhou, Jiangxi, 341100, China.
Int J Nanomedicine. 2023 Jun 29;18:3509-3534. doi: 10.2147/IJN.S408905. eCollection 2023.
Bone tissue engineering is a promising method to treat bone defects. However, the current methods of preparing composite materials that mimic the complex structure and biological activity of natural bone are challenging for recruitment of bone marrow mesenchymal stem cells (BMSCs), which affects the application of these materials in situ bone regeneration. Hollow hydroxyapatite microspheres (HHMs) possess a natural porous bone structure, good adsorption, and slow release of chemokines, but have low ability to recruit BMSCs and induce osteogenesis. In this study, The HHM/chitosan (CS) and recombinant human C-X-C motif chemokine ligand 13 (rhCXCL13)-HHM/CS biomimetic scaffolds that optimize bone regeneration and investigated their mechanism of BMSC recruitment and osteogenesis through cell and animal experiments and transcriptomic sequencing.
Evaluate the physical characteristics of the HHM/CS and rhCXCL13-HHM/CS biomimetic scaffolds through Scanning Electron Microscopy (SEM), X-Ray Diffraction (XRD), and the cumulative release curve of rhCXCL13. Transwell migration experiments and co-culture with BMSCs were conducted to study the recruitment ability and osteogenic differentiation of the scaffolds. Transcriptomic sequencing was performed to analyze the osteogenic differentiation mechanism. The osteogenesis and bone healing performance were evaluated using a rabbit radial defect model.
SEM demonstrated that the rhCXCL13-HHM/CS scaffold comprised hydroxyapatite microspheres in a porous three-dimensional network. The rhCXCL13 showed excellent sustained release capability. The rhCXCL13-HHM/CS scaffold could recruit BMSCs and induce bone regeneration. Transcriptome sequencing and experimental results showed that the osteogenesis mechanism of rhCXCL13-HHM/CS was through the PI3K-AKT pathway. In vivo, the rhCXCL13-HHM/CS scaffold significantly promoted osteogenesis and angiogenesis at 12 weeks after surgery.
The rhCXCL13-HHM/CS scaffold demonstrates excellent potential for BMSC recruitment, osteogenesis, vascularized tissue-engineered bone reconstruction, and drug delivery, providing a theoretical basis for material osteogenesis mechanism study and promising clinical applications for treating large bone defects.
骨组织工程是一种有前途的治疗骨缺损的方法。然而,目前制备模拟天然骨复杂结构和生物活性的复合材料的方法对于招募骨髓间充质干细胞(BMSCs)具有挑战性,这影响了这些材料在原位骨再生中的应用。中空羟基磷灰石微球(HHMs)具有天然多孔骨结构、良好的吸附性和趋化因子的缓慢释放,但招募 BMSCs 和诱导成骨的能力较低。在这项研究中,我们优化了骨再生的 HHM/壳聚糖(CS)和重组人 C-X-C 基序趋化因子配体 13(rhCXCL13)-HHM/CS 仿生支架,并通过细胞和动物实验以及转录组测序研究了它们招募 BMSC 和诱导成骨的机制。
通过扫描电子显微镜(SEM)、X 射线衍射(XRD)和 rhCXCL13 的累积释放曲线评估 HHM/CS 和 rhCXCL13-HHM/CS 仿生支架的物理特性。通过 Transwell 迁移实验和与 BMSCs 共培养研究支架的招募能力和成骨分化。进行转录组测序分析成骨分化机制。使用兔桡骨缺损模型评估成骨和骨愈合性能。
SEM 表明,rhCXCL13-HHM/CS 支架由多孔三维网络中的羟基磷灰石微球组成。rhCXCL13 表现出优异的持续释放能力。rhCXCL13-HHM/CS 支架可以招募 BMSCs 并诱导骨再生。转录组测序和实验结果表明,rhCXCL13-HHM/CS 的成骨机制是通过 PI3K-AKT 途径。体内,rhCXCL13-HHM/CS 支架在手术后 12 周时显著促进了成骨和血管生成。
rhCXCL13-HHM/CS 支架在招募 BMSC、成骨、血管化组织工程骨重建和药物输送方面表现出优异的潜力,为材料成骨机制研究提供了理论基础,并为治疗大骨缺损提供了有前景的临床应用。